During the U.S. Virgin Islands’ first dengue outbreak in roughly a decade, medical professionals often waited one to two months for diagnostic results because the territory lacked local testing facilities and every sample had to be shipped off the islands. Those findings emerged from a Centers for Disease Control and Prevention report published in the Morbidity and Mortality Weekly Report.
Once the territory established local dengue testing at its own public health laboratory in October 2024, turnaround times dropped to less than a week. The outbreak, which spanned from January 2024 to June 2025, resulted in 263 confirmed cases and marked the territory’s first confirmed dengue-related fatality since 2005.
When diagnostic confirmation takes weeks, a feverish patient has typically either recovered or worsened long before answers arrive, rendering local health officials unable to track where the virus is actively spreading. An assessment conducted in August and September 2024 by the CDC and the Virgin Islands Department of Health revealed two primary obstacles. Many clinicians had encountered few suspected dengue patients over the preceding ten years and required specialized training in diagnosis, testing, and reporting protocols, alongside the complete absence of local diagnostic testing infrastructure.
Because of these delays, official case counts captured only a fraction of the actual illness. In August 2024, Chief Medical Officer Dr. Tai Hunte-Ceasar warned that many residents were avoiding medical care or testing entirely, leaving the true burden of the virus unknown.
Confirmed infections were distributed across the three major islands, recording 118 cases on St. Croix, 105 on St. Thomas, and 40 on St. John. Approximately 97% of patients had not traveled outside the territory in the two weeks prior to symptom onset, indicating sustained local transmission. Fifteen individuals required hospitalization, staying an average of 4.3 days.
The single reported fatality involved a 63-year-old woman with underlying diabetes. Among the 105 cases with a characterized virus type, 101 were identified as dengue type 2. Three of the four type 3 cases involved individuals who had recently traveled to Puerto Rico.
The public health response extended well beyond establishing laboratory capabilities. Health officials visited 30 medical clinics, conducted 20 clinical training sessions during the fall of 2024, and introduced a dedicated dengue telephone hotline for healthcare providers in October 2024. Authorities also deployed a web-based electronic reporting system to accelerate case notification times.
Simultaneously, mosquito control teams collaborating with the CDC and the Puerto Rico Vector Control Unit executed door-to-door inspections across 25 communities. Personnel inspected 256 yards for potential mosquito breeding sites, applied outdoor larvicide at 167 residences, and distributed approximately 900 passive repellent devices designed to slowly release insecticide indoors. These outreach efforts engaged 420 households and 54 schools.
CDC authors emphasized that maintaining these operational gains is critical. Sustaining capacity for clinical case management, disease surveillance, and vector control between outbreaks remains imperative for mounting rapid responses to future threats.
Dengue transmission is not restricted to U.S. territories. Florida documented 368 locally acquired dengue cases in 2026 as of Oct. 10, according to state health department data. Of those infections, 310 were tied to exposure within Hillsborough County and 37 to Pinellas County, alongside 288 travel-associated cases statewide, including 182 in Miami-Dade County. Nationally, provisional CDC data through late September tallied 2,008 cases across 40 states and territories, which included 916 infections in Puerto Rico.
Medical guidelines indicate that roughly one in four infected individuals becomes ill, while about one in 20 symptomatic patients develops severe dengue. Symptoms typically emerge five to seven days after a mosquito bite, though the incubation window ranges from three to 10 days, presenting with fever, nausea, vomiting, rash, and pain behind the eyes or within muscles, joints, and bones.
Warning signs of severe illness generally manifest 24 to 48 hours after the initial fever subsides. Severe abdominal pain, persistent vomiting, bleeding from the nose or gums, vomiting blood, bloody stools, or extreme lethargy and restlessness require immediate emergency medical evaluation. Health authorities advise patients with suspected dengue to manage fever and pain with acetaminophen while strictly avoiding aspirin and ibuprofen. Residents and travelers can mitigate exposure risks by applying EPA-registered insect repellent, wearing protective clothing, and eliminating standing water around residential properties.
